Advanced Inhalation Therapies Reveals Finances Ahead of $36 Million IPO
Advanced Inhalation revealed its finances for the past 2 years as it plans for its oncoming $36 million initial public offering to raise funds for its device designed to treat severe respiratory infections and lung diseases using a high dose of nitric oxide.
Advanced Inhalation reported losses of $4.6 million, or 41¢ per share for 2014. That’s up nearly 200% from 2013, when the company reported $1.6 million losses, or 14¢ per share.
Help employers find you! Check out all the jobs and post your resume.
Advanced Inhalation reported losses of $4.6 million, or 41¢ per share for 2014. That’s up nearly 200% from 2013, when the company reported $1.6 million losses, or 14¢ per share.
Help employers find you! Check out all the jobs and post your resume.